PULM vs. LIXT, KTTA, OBSV, CLVR, ASLN, CANF, EFTR, CMMB, TRVN, and TFFP
Should you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include Lixte Biotechnology (LIXT), Pasithea Therapeutics (KTTA), ObsEva (OBSV), Clever Leaves (CLVR), ASLAN Pharmaceuticals (ASLN), Can-Fite BioPharma (CANF), eFFECTOR Therapeutics (EFTR), Chemomab Therapeutics (CMMB), Trevena (TRVN), and TFF Pharmaceuticals (TFFP). These companies are all part of the "pharmaceutical preparations" industry.
Pulmatrix (NASDAQ:PULM) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation, earnings and community ranking.
Pulmatrix has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of -0.28, meaning that its stock price is 128% less volatile than the S&P 500.
Pulmatrix currently has a consensus price target of $10.00, suggesting a potential upside of 397.51%. Given Pulmatrix's higher possible upside, equities analysts clearly believe Pulmatrix is more favorable than Lixte Biotechnology.
Lixte Biotechnology has lower revenue, but higher earnings than Pulmatrix. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.
11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 3.6% of Pulmatrix shares are held by insiders. Comparatively, 15.5% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Pulmatrix received 196 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.
In the previous week, Lixte Biotechnology had 1 more articles in the media than Pulmatrix. MarketBeat recorded 3 mentions for Lixte Biotechnology and 2 mentions for Pulmatrix. Lixte Biotechnology's average media sentiment score of 0.09 beat Pulmatrix's score of 0.00 indicating that Lixte Biotechnology is being referred to more favorably in the news media.
Lixte Biotechnology has a net margin of 0.00% compared to Pulmatrix's net margin of -193.49%. Pulmatrix's return on equity of -63.94% beat Lixte Biotechnology's return on equity.
Summary
Pulmatrix beats Lixte Biotechnology on 9 of the 15 factors compared between the two stocks.
Get Pulmatrix News Delivered to You Automatically
Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PULM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulmatrix Competitors List
Related Companies and Tools
